OncoMatch/Clinical Trials/NCT06929624
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Is NCT06929624 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including SHR-A1912 and Rituximab for diffuse large b-cell lymphoma.
Treatment: SHR-A1912 · Rituximab · Gemcitabine Hydrochloride for · Oxaliplatin — This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Prior therapy
Must have received: systemic antitumor therapy
Have received ≥1 line of systemic antitumor therapy.
Cannot have received: stem cell transplant candidate
Exception: patients who have only one prior line therapy and are candidates for stem cell transplantation
Patients who have only one prior line therapy and are candidates for stem cell transplantation [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify